Hatam, N., Dehghani, M., Habibian, M., & Jafari, A. (2015). Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran. Iran J Cancer Prev.
Chicago-tyylinen lähdeviittausHatam, Nahid, Mehdi Dehghani, Mostafa Habibian, ja Abdosaleh Jafari. "Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran." Iran J Cancer Prev 2015.
MLA-viiteHatam, Nahid, Mehdi Dehghani, Mostafa Habibian, ja Abdosaleh Jafari. "Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran." Iran J Cancer Prev 2015.